Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia/reperfusion injury
Author:
Funder
Department of Education of Liaoning Province
Publisher
Elsevier BV
Subject
Neurology,Molecular Biology,Aging,Biochemistry,Biotechnology
Reference133 articles.
1. A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Myocardial Infarction (EMPACT-MI). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04509674, Accessed 26th Apr 2022.
2. Partial inhibition of the ubiquitin-proteasome system ameliorates cardiac dysfunction following ischemia-reperfusion in the presence of high glucose;Adams;Cardiovasc Diabetol.,2015
3. Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022;American Diabetes Association;Diabetes Care,2022
4. Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome;Ammar;Inflammopharmacology,2022
5. Epicardial adipose tissue and cardiovascular diseases;Ansaldo;Int J. Cardiol.,2019
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The cGAS-STING Pathway: A New Therapeutic Target for Ischemia–Reperfusion Injury in Acute Myocardial Infarction?;Biomedicines;2024-08-02
2. Canagliflozin attenuates post-resuscitation myocardial dysfunction in diabetic rats by inhibiting autophagy through the PI3K/Akt/mTOR pathway;iScience;2024-08
3. The benefits of oral glucose-lowering agents: GLP-1 receptor agonists, DPP-4 and SGLT-2 inhibitors on myocardial ischaemia/reperfusion injury;European Journal of Pharmacology;2024-08
4. ACTIVATION OF KLOTHO/SIRT1 SIGNALING PATHWAY ATTENUATES MYOCARDIAL ISCHEMIA REPERFUSION INJURY IN DIABETIC RATS;Shock;2024-06-21
5. Stem Cell Therapy against Ischemic Heart Disease;International Journal of Molecular Sciences;2024-03-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3